LCM
RPTX

Lynx1 Capital Management’s Repare Therapeutics RPTX Stock Holding History

Lynx1 Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-79,176
Closed -$104K – 19
2024
Q4 		$104K Buy
+79,176
New +$236K 0.04% 18

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Lynx1 Capital Management's RPTX Position: Q1 2025 in Review

Lynx1 Capital Management sold out of Repare Therapeutics (RPTX) in Q1 2025, closing a stake of 79,176 shares — an estimated $104K sold.

Lynx1 Capital Management first reported a position in RPTX in Q4 2024 and held it in 1 quarter. The position peaked at $104K in Q4 2024. 50 funds tracked by Wall St. Rank hold RPTX as of Q1 2025.

  • Lynx1 Capital Management reported no remaining Repare Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 79,176 Repare Therapeutics shares in Q1 2025, an estimated $104K.
  • Lynx1 Capital Management first reported a position in Repare Therapeutics in Q4 2024 and held it in 1 quarter.
  • Lynx1 Capital Management's Repare Therapeutics position peaked at $104K in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2025.

Based on Lynx1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.